Menu
Annual · values202520242023202220212020201920182017201620152014
Operating Cash Flow-26.55 M USD-28.20 M USD-29.06 M USD-28.36 M USD-24.25 M USD-16.93 M USD-12.44 M USD-11.32 M USD-7.97 M USD-5.90 M USD-2.39 M USD-183164 USD
Depreciation & Amortization1432 USD2668 USD2923 USD1492 USD844 USD893 USD1753 USD2632 USD1343 USD0 USD
Stock-Based Compensation10.84 M USD11.84 M USD6.62 M USD3.91 M USD1.45 M USD803261 USD715983 USD779701 USD986620 USD732151 USD486271 USD470185 USD
Capital Expenditures6938 USD1831 USD2126 USD
Cash Flow from Investing-5.75 M USD-5.00 M USD-40.01 M USD-1831 USD-2126 USD255748 USD
Cash Flow from Financing33.30 M USD9.97 M USD13.83 M USD120.47 M USD22.90 M USD11.15 M USD17.30 M USD10.88 M USD5.26 M USD1.51 M USD1.68 M USD
Dividends Paid
Stock Buybacks
Free Cash Flow-24.26 M USD-16.93 M USD-7.97 M USD

Citius Pharmaceuticals, Inc. is a late-stage biopharmaceutical company specializing in the development and commercialization of first-in-class critical care products. The company focuses on innovative therapies primarily in anti-infectives, oncology, adjunct cancer care, stem cell therapy, and unique prescription products. Its diverse pipeline includes candidates targeting serious medical conditions, reflecting a commitment to advancing treatments that address critical unmet needs in healthcare. With a strategic emphasis on critical care and oncology-related therapeutics, Citius plays a significant role in the pharmaceutical industry by aiming to improve patient outcomes through novel drug development. Headquartered in Cranford, New Jersey, Citius Pharmaceuticals leverages its clinical expertise to progress products through late-stage development toward commercialization.